Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gian Maria Pasinetti

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 11, 2012
Ocular surface disease and glaucoma: how to evaluate impact on quality of lifeGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
European Journal of Ophthalmology|December 9, 2010
Do adherence rates and glaucomatous visual field progression correlate?Gemma C M Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Expert Opinion on Pharmacotherapy|June 18, 2011
From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch studyGemma Caterina Maria Rossi, Gian Maria Pasinetti, Francesco Sandolo, et al.
International Ophthalmology|June 9, 2018
Prevalence of dry eye in video display terminal users: a cross-sectional Caucasian study in ItalyGemma Caterina Maria Rossi, Luigia Scudeller, Federica Bettio, et al.
European Journal of Ophthalmology|June 25, 2009
Dry eye syndrome-related quality of life in glaucoma patientsGemma Caterina Maria Rossi, Carmine Tinelli, Gian Maria Pasinetti, et al.
Expert Opinion on Drug Safety|March 12, 2015
From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerabilityGemma Caterina Maria Rossi, Luigia Scudeller, Teresa Rolle, et al.
European Journal of Ophthalmology|January 22, 2013
Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patientsGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Expert Opinion on Pharmacotherapy|February 19, 2010
Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combinationGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Vision (Basel, Switzerland)|July 27, 2022
Randomised, Single Blind, Controlled, Three-Month Clinical Trial on the Evaluation and Treatment of the Ocular Surface Damage Following PhacoemulsificationGemma Caterina Maria Rossi, Carmine Tinelli, Giovanni Milano, et al.
Expert Opinion on Drug Safety|June 14, 2012
Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patientsGemma Caterina Maria Rossi, Gian Maria Pasinetti, Marta Raimondi, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 11, 2012
Ocular surface disease and glaucoma: how to evaluate impact on quality of lifeGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
European Journal of Ophthalmology|December 9, 2010
Do adherence rates and glaucomatous visual field progression correlate?Gemma C M Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Expert Opinion on Pharmacotherapy|June 18, 2011
From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch studyGemma Caterina Maria Rossi, Gian Maria Pasinetti, Francesco Sandolo, et al.
International Ophthalmology|June 9, 2018
Prevalence of dry eye in video display terminal users: a cross-sectional Caucasian study in ItalyGemma Caterina Maria Rossi, Luigia Scudeller, Federica Bettio, et al.
European Journal of Ophthalmology|June 25, 2009
Dry eye syndrome-related quality of life in glaucoma patientsGemma Caterina Maria Rossi, Carmine Tinelli, Gian Maria Pasinetti, et al.
Expert Opinion on Drug Safety|March 12, 2015
From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerabilityGemma Caterina Maria Rossi, Luigia Scudeller, Teresa Rolle, et al.
European Journal of Ophthalmology|January 22, 2013
Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patientsGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Expert Opinion on Pharmacotherapy|February 19, 2010
Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combinationGemma Caterina Maria Rossi, Gian Maria Pasinetti, Luigia Scudeller, et al.
Vision (Basel, Switzerland)|July 27, 2022
Randomised, Single Blind, Controlled, Three-Month Clinical Trial on the Evaluation and Treatment of the Ocular Surface Damage Following PhacoemulsificationGemma Caterina Maria Rossi, Carmine Tinelli, Giovanni Milano, et al.
Expert Opinion on Drug Safety|June 14, 2012
Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patientsGemma Caterina Maria Rossi, Gian Maria Pasinetti, Marta Raimondi, et al.
Pageof 2